← SynDRA
GLESATINIB
SynDRA canonical compound SYN0039144 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | AXL | FLT1 | FLT4 | KDR | MET | MST1R | TEK |
|---|
| Mechanism of action | tyrosine kinase inhibitor |
|---|
All known targets
- KDR
- MET
- AXL
- FLT1
- FLT4
- MST1R
- TEK
Mechanisms of action (all sources)
- MET INHIBITOR
- Hepatocyte growth factor receptor inhibitor
- MST1R INHIBITOR
- Macrophage-stimulating protein receptor inhibitor
- FLT1 INHIBITOR
- Vascular endothelial growth factor receptor inhibitor
- FLT4 INHIBITOR
- KDR INHIBITOR
- TEK INHIBITOR
- Tyrosine-protein kinase TIE-2 inhibitor
- tyrosine kinase inhibitor
- VEGFR inhibitor
Cross-references
Synonyms
- MGCD-265
- MG-90265
- MG-90265X
- MG90265
- MG90265H9
- MG90265X
- MG90265gly
- MGCD265
- MGCD 265
- MGCD-265 analog
- N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide
- UNII-93M6577H9D
- CHEMBL254760
- 93M6577H9D
- n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide
- N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide
- 7Q29OXD98N
- glesatinibum
- RefChem:663075
- TKI MGCD265
- DTXCID701767460
- Glesatinib [USAN]
- A1JSR
- YRCHYHRCBXNYNU-UHFFFAOYSA-N
- Glesatinib free base
- MG265 dihydrochloride
- GLESATINIB [INN]
- Glesatinib dihydrochloride
- Glesatinib (USAN/INN)
- MGCD265 dihydrochloride
- GLESATINIB [WHO-DD]
- UNII-7Q29OXD98N
- SCHEMBL106319
- GTPL9133
- orb1707269
- SCHEMBL29351360
- GLXC-10330
- EX-A4139
- BDBM50625502
Look up GLESATINIB in the interactive SynDRA portal →